Tejasvi Niranjan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tejasvi Niranjan has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Sarah Weckhuysen
Translational Epilepsy Genomics Group, VIB Center for Molecular Neurology, VIB
2 shared publications - Wouter De Coster
Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
2 shared publications - Aivi T. Nguyen
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
1 shared publication Amelie T. van der Ven
Institute of Human Genetics, University Medical Center Hamburg-Eppendorf
1 shared publicationAndrea Rüegger
University Children Hospital Zurich
1 shared publicationAndrew King
Department of Basic and Clinical Neuroscience, London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
1 shared publication
Latest Publications
- Open Access
Long-read genome sequencing resolves complex structural variants in exome-negative developmental and epileptic encephalopathy
Background and Objectives: Developmental and Epileptic Encephalopathies (DEEs) encompass a clinically and molecularly heterogeneous group of mainly genetic disorders. Despite standard genetic testing, approximately two-thirds of patients remain undiagnosed. Pathogenic noncoding and structural variants (SVs), particularly complex rearrangements that are difficult to detect or resolve using short-read sequencing, may contribute to this diagnostic gap. To evaluate the diagnostic contribution of long-read genome sequencing (lrGS), we recruited a cohort of 124 families with sporadic DEE who remained unsolved by prior ES. Methods: Trio lrGS (Oxford Nanopore or PacBio HiFi) was performed, complemented zby short-read genome sequencing (srGS) and mRNA sequencing (blood or fibroblast) of index cases, where available. Comprehensive variant analysis included small nucleotide variants (SNVs), indels, SVs, and short tandem repeats. To identify the diagnostic yield of each method, we compared lrGS, srGS and ES re-analysis, and evaluated the additional value of RNA sequencing. Results: We established a diagnosis in 21 of 124 families (16.9%). Fourteen variants were retrospectively detectable in prior ES., Two cases with non-coding variants in SCN1A and RNU2-2 were detectable by both srGS and lrGS. Five SVs also required genome sequencing (5.6% of the total cohort), three of which could be detected, but not confidently resolved by srGS due to breakpoint complexity, repeat-mediated rearrangements, and large copy-neutral events: LrGS enabled accurate characterization of Alu-mediated CDKL5 and STXBP1 deletions and a MEF2C deletion with large inversion. A copy-neutral SCN1A inversion was well characterizable by both srGS and lrGS. One balanced translocation t(X;17) disrupting CDKL5 was resolved by lrGS (srGS unavailable). RNA sequencing confirmed pathogenicity of two SVs including t(X;17), the MEF2C deletion with inversion, and two CNVs. In addition, ZNF569 and ZNF570 emerged as candidate epilepsy genes from our cohort. Discussion: In ES-negative DEE, the incremental diagnostic yield of genome sequencing was modest, while lrGS provided particular value for the structural resolution of complex rearrangements, especially those involving repetitive sequences. The finding that two-thirds of diagnoses were retrospectively detectable in prior ES highlights the substantial value of systematic reanalysis. Further gains from genome sequencing may increasingly depend on improved interpretation of non-coding variation and integration of long-read-specific information. Our findings indicate that complex SVs represent the class for which lrGS currently yields the most distinctive diagnostic information.
Open AccessLong-read genome sequencing resolves complex structural variants in exome-negative developmental and epileptic encephalopathy
Background and Objectives: Developmental and Epileptic Encephalopathies (DEEs) encompass a clinically and molecularly heterogeneous group of mainly genetic disorders. Despite standard genetic testing, approximately two-thirds of patients remain undiagnosed. Pathogenic noncoding and structural variants (SVs), particularly complex rearrangements that are difficult to detect or resolve using short-read sequencing, may contribute to this diagnostic gap. To evaluate the diagnostic contribution of long-read genome sequencing (lrGS), we recruited a cohort of 124 families with sporadic DEE who remained unsolved by prior ES. Methods: Trio lrGS (Oxford Nanopore or PacBio HiFi) was performed, complemented zby short-read genome sequencing (srGS) and mRNA sequencing (blood or fibroblast) of index cases, where available. Comprehensive variant analysis included small nucleotide variants (SNVs), indels, SVs, and short tandem repeats. To identify the diagnostic yield of each method, we compared lrGS, srGS and ES re-analysis, and evaluated the additional value of RNA sequencing. Results: We established a diagnosis in 21 of 124 families (16.9%). Fourteen variants were retrospectively detectable in prior ES., Two cases with non-coding variants in SCN1A and RNU2-2 were detectable by both srGS and lrGS. Five SVs also required genome sequencing (5.6% of the total cohort), three of which could be detected, but not confidently resolved by srGS due to breakpoint complexity, repeat-mediated rearrangements, and large copy-neutral events: LrGS enabled accurate characterization of Alu-mediated CDKL5 and STXBP1 deletions and a MEF2C deletion with large inversion. A copy-neutral SCN1A inversion was well characterizable by both srGS and lrGS. One balanced translocation t(X;17) disrupting CDKL5 was resolved by lrGS (srGS unavailable). RNA sequencing confirmed pathogenicity of two SVs including t(X;17), the MEF2C deletion with inversion, and two CNVs. In addition, ZNF569 and ZNF570 emerged as candidate epilepsy genes from our cohort. Discussion: In ES-negative DEE, the incremental diagnostic yield of genome sequencing was modest, while lrGS provided particular value for the structural resolution of complex rearrangements, especially those involving repetitive sequences. The finding that two-thirds of diagnoses were retrospectively detectable in prior ES highlights the substantial value of systematic reanalysis. Further gains from genome sequencing may increasingly depend on improved interpretation of non-coding variation and integration of long-read-specific information. Our findings indicate that complex SVs represent the class for which lrGS currently yields the most distinctive diagnostic information.
- 4 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (12) , 2738-2744
Abidi Syndrome and Another Family With X‐Linked Intellectual Disability Have TAF1 Variants and Reduced Phosphorylation of RNA Polymerase II Associated Protein 74
Genetic alterations in TATA box binding protein‐associated factor 1 ( TAF1 ) have been found in an X‐linked intellectual disability (XLID) syndrome with variable somatic features (OMIM 300966) and X‐linked dystonia‐Parkinsonism syndrome (OMIM 314250). Abidi syndrome (OMIM 300262) was first described in a large, three‐generation family containing eight affected males with intellectual disability and variable somatic features. A single base substitution that alters the translation initiation codon of TAF1 , c.1A>C (p.Met1?), was found in affected males from the original Abidi syndrome family by X‐exome sequencing. A missense variant in the C‐terminal domain of TAF1, c.4286A>C (p.Gln1429Pro), was identified in another XLID family including three males with intellectual disability and variable somatic features using the same approach. Both variants were found segregating with the phenotype in the respective families and are predicted to be deleterious by in silico analysis. The N‐ and C‐terminal domains of TAF1 are known to possess a serine/threonine kinase activity that selectively phosphorylates RNA polymerase II‐associated protein 74 (RAP74). Lymphoblasts carrying either the p.Met1? or the p.Gln1429Pro variants from probands in these two families were studied using a phosphorylation‐specific antibody and found to have reduced phosphorylation of RAP74. This study expands the phenotypic spectrum of TAF1‐related XLID and implicates reduced RAP74 phosphorylation as a potential mechanism.
- 4 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (12) , 2738-2744
Abidi Syndrome and Another Family With X‐Linked Intellectual Disability Have TAF1 Variants and Reduced Phosphorylation of RNA Polymerase II Associated Protein 74
Genetic alterations in TATA box binding protein‐associated factor 1 ( TAF1 ) have been found in an X‐linked intellectual disability (XLID) syndrome with variable somatic features (OMIM 300966) and X‐linked dystonia‐Parkinsonism syndrome (OMIM 314250). Abidi syndrome (OMIM 300262) was first described in a large, three‐generation family containing eight affected males with intellectual disability and variable somatic features. A single base substitution that alters the translation initiation codon of TAF1 , c.1A>C (p.Met1?), was found in affected males from the original Abidi syndrome family by X‐exome sequencing. A missense variant in the C‐terminal domain of TAF1, c.4286A>C (p.Gln1429Pro), was identified in another XLID family including three males with intellectual disability and variable somatic features using the same approach. Both variants were found segregating with the phenotype in the respective families and are predicted to be deleterious by in silico analysis. The N‐ and C‐terminal domains of TAF1 are known to possess a serine/threonine kinase activity that selectively phosphorylates RNA polymerase II‐associated protein 74 (RAP74). Lymphoblasts carrying either the p.Met1? or the p.Gln1429Pro variants from probands in these two families were studied using a phosphorylation‐specific antibody and found to have reduced phosphorylation of RAP74. This study expands the phenotypic spectrum of TAF1‐related XLID and implicates reduced RAP74 phosphorylation as a potential mechanism.
- Open Access
- 6 July 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-27
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes
Background: In the last decade, the importance of DNA methylation in the functioning of the central nervous system has been highlighted through associations between methylation changes and differential expression of key genes involved in aging and neurodegenerative diseases. In frontotemporal lobar degeneration (FTLD), aberrant methylation has been reported in causal disease genes including GRN and C9orf72; however, the genome-wide contribution of epigenetic changes to the development of FTLD remains largely unexplored. Methods: We performed reduced representation bisulfite sequencing of matched pairs of post-mortem tissue from frontal cortex (FCX) and cerebellum (CER) from pathologically confirmed FTLD patients with TDP-43 pathology (FTLD-TDP) further divided into five subtypes and including both sporadic and genetic forms (N = 25 pairs per group), and neuropathologically normal controls (N = 42 pairs). Case-control differential methylation analyses were performed, both at the individual CpG level, and in regions of grouped CpGs (differentially methylated regions; DMRs), either including all genomic locations or only gene promoters. Gene Ontology (GO) analyses were then performed using all differentially methylated genes in each group of sporadic patients. Finally, additional datasets were queried to prioritize candidate genes for follow-up. Results: Using the largest FTLD-TDP DNA methylation dataset generated to date, we identified thousands of differentially methylated CpGs (FCX = 6,520; CER = 7,134) and several hundred DMRs in FTLD-TDP brains (FCX = 134; CER = 219). Of these, less than 10% are shared between pathological subgroups. Combining additional datasets, we identified, validated and replicated hypomethylation of CAMTA1 in TDP-A potentially also impacting additional genes in the locus. GO analysis further implicated DNA methylation in myelination and developmental processes, as well as important disease-relevant mechanisms with subtype specificity such as protein phosphorylation and DNA damage repair in TDP-A, cholesterol biosynthesis in TDP-B, and protein localization in TDP-C. Conclusions: We identify methylation changes in all FTLD-TDP patient groups and show that most changes are unique to a specific pathological FTLD-TDP subtype, suggesting that these subtypes not only have distinct transcriptomic and genetic signatures, but are also epigenetically distinct. Our study constitutes an invaluable resource to the community and highlights the need for further studies to profile additional epigenetic layers within each FTLD-TDP pathological subtype.
- 6 July 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-27
Open AccessMethylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes
Background: In the last decade, the importance of DNA methylation in the functioning of the central nervous system has been highlighted through associations between methylation changes and differential expression of key genes involved in aging and neurodegenerative diseases. In frontotemporal lobar degeneration (FTLD), aberrant methylation has been reported in causal disease genes including GRN and C9orf72; however, the genome-wide contribution of epigenetic changes to the development of FTLD remains largely unexplored. Methods: We performed reduced representation bisulfite sequencing of matched pairs of post-mortem tissue from frontal cortex (FCX) and cerebellum (CER) from pathologically confirmed FTLD patients with TDP-43 pathology (FTLD-TDP) further divided into five subtypes and including both sporadic and genetic forms (N = 25 pairs per group), and neuropathologically normal controls (N = 42 pairs). Case-control differential methylation analyses were performed, both at the individual CpG level, and in regions of grouped CpGs (differentially methylated regions; DMRs), either including all genomic locations or only gene promoters. Gene Ontology (GO) analyses were then performed using all differentially methylated genes in each group of sporadic patients. Finally, additional datasets were queried to prioritize candidate genes for follow-up. Results: Using the largest FTLD-TDP DNA methylation dataset generated to date, we identified thousands of differentially methylated CpGs (FCX = 6,520; CER = 7,134) and several hundred DMRs in FTLD-TDP brains (FCX = 134; CER = 219). Of these, less than 10% are shared between pathological subgroups. Combining additional datasets, we identified, validated and replicated hypomethylation of CAMTA1 in TDP-A potentially also impacting additional genes in the locus. GO analysis further implicated DNA methylation in myelination and developmental processes, as well as important disease-relevant mechanisms with subtype specificity such as protein phosphorylation and DNA damage repair in TDP-A, cholesterol biosynthesis in TDP-B, and protein localization in TDP-C. Conclusions: We identify methylation changes in all FTLD-TDP patient groups and show that most changes are unique to a specific pathological FTLD-TDP subtype, suggesting that these subtypes not only have distinct transcriptomic and genetic signatures, but are also epigenetically distinct. Our study constitutes an invaluable resource to the community and highlights the need for further studies to profile additional epigenetic layers within each FTLD-TDP pathological subtype.